Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 496-504

  Yau, Thomas ^a,b   Cheng, Paul N ^c   Chan, Pierre ^d   Chen, Li ^c   Yuen, Jimmy ^e   Pang, Roberta ^a   Fan, Sheung Tat ^a,b   Wheatley, Denys N ^c   Poon, Ronnie T ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Bio Cancer Treatment International Limited   (Hong Kong)

^d RUTTONJEE HOSPITAL   (Hong Kong)

^e HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Advanced HCC; Arginase; Arginine; Peg rhArg1

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; ARGINASE I, HUMAN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HALF LIFE TIME; HUMAN; LIVER NEOPLASMS; MALE; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ARGINASE; CARCINOMA, HEPATOCELLULAR; CHEMISTRY, PHARMACEUTICAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 84939954648     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0200-8     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2):153-156. doi: 10.1002/ijc.1440
2. Poon RT, Fan ST, Tsang FH, Wong J (2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235(4):466-486
3. Wheatley DN (2004) Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anti-Cancer Drugs 15(9):825-833
4. Wheatley DN, Campbell E, Lai PB, Cheng PN (2005) A rational approach to the systemic treatment of cancer involving medium-term depletion of arginine. Gene Ther Mol Biol 9:33-40
5. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC (2007) Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67(1):309-317. doi: 10.1158/0008-5472.CAN-06-1945
6. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22(10):1815-1822. doi: 10.1200/JCO.2004.11.120
7. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT (2010) A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103(7):954-960. doi: 10.1038/sj.bjc.6605856
8. Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, Pang R, Fan ST, Poon RT (2013) A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 31(1):99-107. doi: 10.1007/s10637-012-9807-9
9. Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT, Pang RW (2012) Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr Cancer Drug Targets 12(9):1233-1243
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-430
11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-181. doi: 10.1016/S1053-4296(03)00031-6
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
13. Cheng PN, Leung YC, Lo WH, Tsui SM, Lam KC (2005) Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett 224(1):67-80. doi: 10.1016/j.canlet.2004.10.050
14. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT (2008) A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 113(10):2742-2751. doi: 10.1002/cncr.23878
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
17. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E (2013) Sunitinib versus Sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31(32):4067-4075. doi: 10.1200/JCO.2012.45.8372
18. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y (2013) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31(28):3501-3508. doi: 10.1200/JCO.2012.44.5643
19. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97(20):1532-1538. doi: 10.1093/jnci/dji315
20. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 5(7):1676-1681
21. Wheatley DN (2012) Amino acid deprivation as the primary intervention in cancer therapy: cellular basis of effective combinatorial therapy with arginase as the platform. Biomed Res 23:149-154
22. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ (2008) Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123(8):1950-1955. doi: 10.1002/ijc.23723
23. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100(4):826-833. doi: 10.1002/cncr.20057
24. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120(4):897-905. doi: 10.1002/ijc.22322
25. Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PN, Hsueh CT (2012) Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol 5:17. doi: 10.1186/1756-8722-5-17
26. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC (2009) Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 277(1):91-100. doi: 10.1016/j.canlet.2008.11.031
27. Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH, Leung YC (2011) Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 24(2):366-376. doi: 10.1111/j.1755-148X.2010.00798.x
28. Sugimura K, Ohno T, Kusuyama T, Azuma I (1992) High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res 2(3):191-196
29. Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K (1992) In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer 51(2):244-249
30. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, Arnold S, Cheng PN, Wheatley DN, Lo WH, Leung YC (2009) Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 9:9. doi: 10.1186/1475-2867-9-9
31. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, Cole J, Rodriguez PC (2010) Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 115(25):5214-5221. doi: 10.1182/blood-2009-12-258822
32. Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA (2002) Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit: Int Med J Exp Clin Res 8(7):BR248-BR253